Making cell therapies possible: Liberating patients with living therapeutics.

Learn about the discoveries that enable our approach  

The Sigilon Therapeutics Mission

Our mission at Sigilon Therapeutics is to develop improved treatments for chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the foreign body response (fibrosis). Treatments based on the Sigilon Therapeutics technology platform will act as responsive “living therapeutics” that can provide more natural control for diseases currently treated with intermittent injection or infusion.

Learn about our novel approach to developing new therapies for patients ›